International drug companies are threatening to remove medicines from the market if Australia doesn’t offer them a better price. Here’s what’s at stake.
Articles on Pharmaceutical Benefits Advisory Committee
Displaying all articles
The PM says the PBS is not up for negotiation, while the opposition leader says it’s the envy of the world. But how did we get this system, and how does it compare?
Australia is the first country in the world to legalise the medical use of psychedelics. But without a public subsidy, few Australians will be able to afford them.
Here’s how the Turnbull/Morrison government performed on hospitals, primary care, pharmaceuticals and private health insurance.
Most of us would agree that cancer drugs should be listed on the PBS, no matter how dear. But our health system can’t afford all of them. How then are decisions about which drugs to subsidise made?
Top contributors
-
Research Fellow, Flinders University
-
Professor of Health Economics, Flinders University
-
Associate Professor in Health Economics, Flinders University
-
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
-
Professor, Monash University
-
Professor, Monash University
-
Senior research fellow, Monash University
-
Associate Lecturer, School of Pharmacy, University of Sydney
-
Associate Lecturer, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
University of Sydney
-
Associate Professor, Macquarie University Centre for the Health Economy, Macquarie University